BiomX Inc. (NYSE American: PHGE), the Israeli-based clinical-stage phage therapy company, publicly disclosed on March 27, 2026, that it received a formal non-compliance notice from the NYSE American LLC on March 25, 2026. The notice cites a stockholders' equity deficiency across three separate listing standard violations and arrives at a moment when the company is simultaneously managing a going concern qualification, a critical clinical trial, and a narrow window to submit a remediation plan by April 24, 2026.
This is not a delisting order. But it is a structured regulatory warning that places BiomX's continued listing status on a documented timeline with binding deadlines and defined consequences if those deadlines are not met.
Who Issued the NYSE American Compliance Notice and What It Covers
The Three Listing Standard Violations BiomX Was Cited For
On March 25, 2026, BiomX received a notice from the staff of NYSE American LLC stating that the company was not in compliance with the NYSE American's continued listing standards in Part 10, Section 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide.
The three specific thresholds BiomX failed to meet are as follows.
Section 1003(a)(i) requires a listed company to have stockholders' equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years.
Section 1003(a)(ii) requires a listed company to have stockholders' equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years.
Section 1003(a)(iii) requires a listed company to have stockholders' equity of at least $6.0 million if it has reported losses from continuing operations and/or net losses in five or more of its most recent fiscal years.
BiomX breached all three thresholds simultaneously, reflecting a pattern of persistent net losses across multiple consecutive fiscal years that has eroded its equity base below every applicable regulatory floor.
Who Is Affected by the Notice and What Happens to PHGE Stock
The notice has no immediate effect on the listing or trading of BiomX's common stock, par value $0.0001 per share, and the common stock will continue to trade on the NYSE American under the symbol "PHGE." The company's receipt of the notice does not affect its business, operations, or reporting requirements with the Securities and Exchange Commission.
What investors should monitor closely is the ".BC" designation that NYSE American attaches to non-compliant listings. This indicator signals to the market that the stock is trading below compliance with continued listing standards, which institutional investors and index funds use as a formal screening filter. The designation does not restrict trading but it does affect how the stock is perceived by quantitative screening models and compliance-driven portfolio managers.
Who Is Responsible for Submitting BiomX's Compliance Plan
The April 24, 2026 Deadline and What It Requires
In connection with its non-compliance with Section 1003(a)(i), Section 1003(a)(ii), and Section 1003(a)(iii), BiomX must submit a compliance plan to the NYSE American by April 24, 2026, advising of actions it has taken or will take to regain compliance with the continued listing standards.
BiomX's management is reviewing its options to address the deficiencies and expects to submit a compliance plan on or before the deadline set by the NYSE American.
The compliance plan is not a simple letter. It is a structured document that must outline specific capital actions, timelines for execution, and measurable milestones toward restoring stockholders' equity above the applicable thresholds. NYSE American staff then evaluates whether the plan is credible, actionable, and likely to succeed within the exchange's prescribed remediation window, which typically extends up to 18 months from the date of the original notice.
Who Triggered the Going Concern Qualification in BiomX's Audit Opinion
What the Form 10-K Filing Revealed
As previously disclosed in its annual report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the Securities and Exchange Commission on February 19, 2026, the audit opinion contained a going concern qualification from the company's independent registered public accounting firm.
A going concern qualification is one of the most significant disclosures an auditor can issue. It formally states that the auditor has substantial doubt about whether the company can continue operating for the next 12 months without securing additional capital. For BiomX, this qualification was not issued in isolation. It followed a year in which the company reported a projected full-year 2025 net loss of approximately $34 million and carried a cash position that analysts had estimated would fund operations only into early 2026 without a new financing event.
The notice also indicates that BiomX is not currently eligible for any exemption in Section 1003(a) of the Company Guide, including the exemption provided for companies with total value of market capitalization exceeding $50 million, among other qualifying criteria.
Who Has Flagged BiomX's Financial Condition Before This Notice
A Pattern of Compliance Risk Since May 2024
This is not the first time BiomX has stood before NYSE American on these exact grounds. BiomX previously received a notice of non-compliance from NYSE American on May 23, 2024, due to failing to meet stockholders' equity requirements, and was required to submit a compliance plan by June 22, 2024, with full compliance required by November 23, 2025.
In December 2024, BiomX received written notification from NYSE American, dated December 10, 2024, stating that the company had regained compliance with all NYSE American continued listing standards, having demonstrated compliance for a period of two consecutive quarters pursuant to Section 1009(f) of the Company Guide.
The fact that BiomX regained compliance in December 2024 only to receive a new non-compliance notice in March 2026 illustrates the structural financial fragility of a clinical-stage biotech operating without product revenue while bearing the full cost burden of late-stage clinical development. The window between compliance and deficiency was approximately 15 months.
Who Leads BiomX and What Clinical Progress Justifies Continued Investor Attention
Jonathan Solomon's Position on the BX004 Program
Despite the compliance pressure, BiomX CEO Jonathan Solomon has consistently anchored the company's investor narrative to the clinical value of its phage therapy pipeline, specifically BX004, its lead asset targeting Pseudomonas aeruginosa lung infections in cystic fibrosis patients.
An independent Data Monitoring Committee completed a safety review following adverse events identified in the BX004 Phase 2b trial and recommended that the study continue with revised dosing. Following that review, the study protocol was updated and topline results are now expected in Q2 2026.
Solomon stated publicly that the company remains committed to advancing a potential treatment for the unmet need of Pseudomonas aeruginosa infections in patients with cystic fibrosis, and that it is working closely with its device manufacturer to provide the FDA with the remaining clarifications, expressing confidence in the path forward for BX004.
Who Validated BiomX's Phage Therapy Science
The scientific credibility behind BiomX's platform is not in dispute. Phase 1b/2a results published in Nature Communications demonstrated that BX004 achieved a 2.7 log reduction, approximately a 500-fold greater bacterial reduction compared to placebo, with no emergent resistance and preservation of the healthy microbiome, addressing key limitations of traditional antibiotics in this patient population.
BX004 holds both Fast Track designation and Orphan Drug Designation from the FDA, regulatory designations that could potentially streamline the approval pathway and reduce the time and cost required for commercialization if topline Phase 2b results are positive.
The tension at the core of BiomX's current situation is direct: the science is peer-reviewed and published in a premier journal, the regulatory designations are secured, but the capital structure does not yet support the company's survival through the finish line without a substantial financing event.
Who Bears the Risk If BiomX Fails to Submit a Credible Compliance Plan
What Happens If NYSE American Rejects the Plan
If BiomX fails to submit a plan by April 24, 2026, or if NYSE American determines that the submitted plan is insufficient, the exchange can initiate delisting procedures. At that point, BiomX would have the right to appeal to an NYSE American Listings Qualifications Panel, a process that extends the timeline but does not guarantee a different outcome.
A formal delisting would force BiomX's stock to trade on the OTC Markets, which carries immediate consequences: reduced institutional eligibility, lower daily trading volume, wider bid-ask spreads, and removal from index-eligible universes that feed certain ETF and passive fund holdings. For a company seeking to raise capital to fund clinical operations, a delisting scenario would significantly complicate any equity financing effort at a moment when the company can least afford it.